28 Jun Virica Biotech
Jean Simon Diallo, Ph.D., CEO
April 16 | 5:30pm | Salone dei Cavalieri, Section 2
Toronto, Canada
(Private)
Virica develops cell enhancers that improve the yield and quality of vaccines, viral vectors, & cell & gene therapies, allowing developers to economically deploy their products at scale. Virica’s Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by cellular defenses in manufacturing cells. Purpose formulated VSE combinations substantially increase manufacturing yields & reduce the cost of goods for a range of products. We leverage our proprietary High-throughput Virology platform and DOE workflows to identify optimal cell enhancing compounds, & production parameters to help drive up productivity & drive down costs in the manufacturing of vaccines, gene therapies, & cell therapies. www.viricabiotech.com
